Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Denileukin Diftitox
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Citius Oncology
Deal Size : Undisclosed
Deal Type : Agreement
Citius Expands Distribution Network for LYMPHIR with Cencora
Details : Under the agreement, Cencora will execute the distribution process of Lymphir (denileukin diftitox). It is being indicated for the treatemnt of Stage I-III cutaneous T-cell lymphoma.
Product Name : Lymphir
Product Type : Protein
Upfront Cash : Undisclosed
July 15, 2025
Lead Product(s) : Denileukin Diftitox
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Citius Oncology
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Bevacizumab
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Recipient : Outlook Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : ONS-5010 is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet AMD and other retinal diseases.
Product Name : Lytenava
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
September 27, 2022
Lead Product(s) : Bevacizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : Outlook Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement